23:19 EDT 13 Apr 2018 | BioPortfolio Reports
Summary
Neurodyn Inc Neurodyn is a provider of validation and development of bioactives for neuroprotection and early treatment of neurological diseases. The company's products include Memogain, progranulin, neuroprotectant, and nerve pain treatment. Its Neuroprotectant, is a saponin based bioactive, which is used for protection of early stage Parkinson 's disease, Progranulin is a bioactive used for the neuroprotection and treatment of Parkinson's disease, and nerve pain treatment is a lipophilic compound which acts as an antagonists for sodium and TRP ion channels. Neurodyn develops bioactives for neuroprotection and for treating neurological diseases. The company provides contract research services for medicinal chemistry. It caters to pharmaceutical and consumer health players. Neurodyn is headquartered in Charlottetown, Canada. Neurodyn Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Neurodyn Inc  Pharmaceuticals  Healthcare  Deals and Alliances Profile Report Updated 13032018 Prices from USD $250

by Peter Moreira
on Dec 30, 2013
Robert Niven walked into the CarbonCure Technologies holiday party earlier this month with an expression that was equal parts elation and weariness. Not only had the company’s Founder and CEO spent the week closing a few sales deals, he had also announced a $3.5 million round of financing led by BDC Venture Capital to fund R&D and expand its sales team. The Halifax cleantech company, which is pioneering a low-carbon process of manufacturing concrete products, was part of a healthy trend that developed in the Atlantic Canada startup community in 2013 – a growing flow of institutional money coming into the region from elsewhere. This trend is no accident. The Atlantic Canadian ecosystem has been improving since two companies founded in New Brunswick, Radian6 and Q1 Labs, announced exits in 2011. In fact, there was a succession of new programs and events unveiled in 2013 alone that are focused on attracting capital from institutional investors. “There are three reasons this funding has happened this year, and I think it started with Radian6 and Q1 Labs winning the CVCA Deal of the Year awards back to back in 2011 and 2012,” said Gerry Pond, Chairman of East Valley Ventures investment and mentorship group in Saint John. Pond also said that the Atlantic Canadian ecosystem now features more incubators, accelerators and support organizations than ever before, and they are nurturing the quality of company that attracts capital. Finally, he said the “next generation” of angel investors in the region, such as GoInstant Co-Founder Jevon MacDonald and Clarity Founder Dan Martell, has excellent ties with funders outside the region and are helping to develop these links. Most institutional investment in Atlantic Canada has traditionally come from by local VC institutions, such as provincially backed Innovacorp , Nova Scotia Business Inc. and the New Brunswick Innovation Foundation , or the labour-sponsored GrowthWorks Atlantic . In 2012, for example, there were no announcements of institutional financings of more than $1 million from outside the region. This year, the biggest investment deal was actually a buy-in from a private equity firm – Toronto-based Imperial Capital’s $17 million investment in Halifax pharmaceutical services company STI Technologies Ltd. That was followed by Karma Gaming of Halifax, which raised a total of $5 million from: Rho Ventures , a leading VC fund based in New York, Silicon Valley and Montreal; Vanedge of Vancouver; and Halifax’s Innovacorp. Neurodyn Inc ., the Charlottetown biotech developing early treatments for neurological diseases, raised $1.5 million, mainly from the Regis Duffy BioScience Fund Inc. of Charlottetown and Mertz Holdings , a family-owned investment fund based in Houston, Texas. Analyze Re , a Halifax company that provides risk assessment for reinsurers, raised almost $1.4 million from Innovacorp, BDC Venture Capital of Montreal and Rho. BDC first invested in Analyze Re by offering $150,000 convertible notes to select graduates of the Launch36 accelerator, one of several Canadian accelerators to benefit from the program. Other Launch36 grads that received the notes were R17 , formerly RUMAnalytics, of Saint John, Eigen Innovations of Fredericton, FoodTender of Moncton and topLog of Halifax. Another development this year that is helping with follow-on funding is the launch of Build Ventures , the regional VC backed by the three Maritime provinces, BDC and private investors. The fund made two investments this year, $1.5 million each in Introhive of Washington and Fredericton, and Affinio of Halifax. Finally, the development of growing Atlantic Canadian companies got a boost from the opening of the incubators Volta Labs in Halifax in May and Planet Hatch in Fredericton in September. Between them, they have graduated four companies that have reached milestones forcing them to find other accommodations. The growth of Startup St. John's in Newfoundland and Labrador complements the establishment of these startup houses. CarbonCure’s Niven warns that recent exits have not quite created the recognition for Atlantic Canadian startups that you might expect. “However, our tech startups are emboldened with unprecedented confidence, access to capital and experience,” he said. “While the threshold is the same, our startup communities are just much better equipped to close the deals. Success breeds more success.”
This article was originally published on Entrevestor , a site which produces daily news reports on the Atlantic Canadian startup community. Tweet
Peter Moreira
Peter Moreira spent more than 30 years in journalism in Asia, Europe and North America.He worked with The Deal of New York, covering M&A, private equity and VC markets in the U.S. and Canada for six years and serving four years as London Bureau Chief. At Bloomberg, he covered European and U.K. banking and finance. He previously worked for the South China Morning Post in Hong Kong,... more
Who's Hiring

Atlantic Canada’s Newsmaker of the Year in Tech: An Influx of Institutional Capital

Kim Richters
Save this article  
Send to  
Galantos Pharma, a pharmaceutical company backed by High-Tech Gründerfonds (HTGF) and KfW, has sold its Alzheimer's drug Memogain to Neurodyn. Memogain will be ready to start in clinical trials in late 2013.Neurodyn is a biotechnology firm based in Canada. It focuses on treatments for neurological conditions.In 2010, Galantos Pharma secured...
To continue reading...

PE-backed Galantos Pharma sells Alzheimer drug

Published on September 5, 2013 at 12:39 AM· No Comments
Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany (galantos.com) all assets related to their Alzheimer's prescription drug candidate - Memogain®. Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed. “We are very pleased to complete this acquisition. Memogain® is a significant improvement over existing Alzheimer's drugs, and is staged for immediate entry into clinical trials. It has the potential to follow a fast-track regulatory pathway in both the US and Europe”
Related Stories
Inhibiting adrenaline receptors reduces breast cancer brain metastases
"We are very pleased to complete this acquisition. Memogain® is a significant improvement over existing Alzheimer's drugs, and is staged for immediate entry into clinical trials. It has the potential to follow a fast-track regulatory pathway in both the US and Europe," said Kenneth Cawkell, Neurodyn CEO. Memogain® is a patented improvement on the generic drug, galantamine, (Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine). Galantamine, a plant-derived compound, is widely prescribed to enhance cognition for the treatment of mild to moderate Alzheimer's disease, but has a limited capacity for brain penetration and significant side effects that limit its effectiveness. Memogain® was developed to have a much higher bioavailability in the brain, without the negative gastro-intestinal side effects that limit patient acceptance. Neurodyn will also investigate the potential for Memogain® to decrease the amyloid plaque burden associated with Alzheimer's disease and to induce new cell growth in regions of the brain affected by the disease. Sales of galantamine are currently in excess of $500 million per year. The worldwide Alzheimer's drug market is currently estimated to exceed $4.2 billion and is growing rapidly due to the aging demographic. Current drugs on the market have significant side effects which limit their effectiveness and reduce their usefulness. The revenue potential for Memogain® could extend beyond the current galantamine market share due to the urgent medical need for Alzheimer's drugs that have increased efficacy and decreased side effects compared to the current anti-dementia drugs. Source:

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

For Dementia in      Alzheimer’s Disease
September 04, 2013 11:00 AM Eastern Daylight Time
CHARLOTTETOWN, Prince Edward Island--( BUSINESS WIRE )--Neurodyn Inc. announced today that it has acquired from Galantos      Pharma GmbH, Mainz, Germany (galantos.com) all assets related to their      Alzheimer’s prescription drug candidate – Memogain®. Memogain® has completed an extensive preclinical development program and      is ready to proceed into Phase 1 clinical trials in late 2013. The terms      of the acquisition were not disclosed. “We are very pleased to complete this acquisition. Memogain® is a      significant improvement over existing Alzheimer’s drugs, and is staged      for immediate entry into clinical trials. It has the potential to follow      a fast-track regulatory pathway in both the US and Europe,” said Kenneth      Cawkell, Neurodyn CEO. Memogain® is a patented improvement on the generic drug, galantamine,      (Nivalin, Razadyne, Razadyne ER, Reminyl, Lycoremine). Galantamine, a      plant-derived compound, is widely prescribed to enhance cognition for      the treatment of mild to moderate Alzheimer's disease, but has a limited      capacity for brain penetration and significant side effects that limit      its effectiveness. Memogain® was developed to have a much higher      bioavailability in the brain, without the negative gastro-intestinal      side effects that limit patient acceptance. Neurodyn will also investigate the potential for Memogain® to decrease      the amyloid plaque burden associated with Alzheimer’s disease and to      induce new cell growth in regions of the brain affected by the disease. Sales of galantamine are currently in excess of $500 million per year. The worldwide Alzheimer’s drug market is currently estimated to exceed      $4.2 billion and is growing rapidly due to the aging demographic. Current drugs on the market have significant side effects which limit      their effectiveness and reduce their usefulness. The revenue potential for Memogain® could extend beyond the current      galantamine market share due to the urgent medical need for Alzheimer’s      drugs that have increased efficacy and decreased side effects compared      to the current anti-dementia drugs. Neurodyn Inc. ( www.neurodyn.ca )      is a Canadian biotechnology company focused on identifying, validating      and developing natural bioactives into both prescription drugs and      natural products for the early treatment of neurological diseases. Neurodyn examines historically-proven natural products to discover key      bioactives which can either be reformulated or repurposed to provide      more effective treatments for neurological conditions. Neurodyn’s lead technologies include ND1208, a neuroprotectant      for use in early stage Parkinson’s disease, which is incorporated into      both a nutrition supplement (in market) and a US-FDA Medical Food      product (under development), Progranulin (ND602), a novel      therapeutic demonstrating pre-clinical efficacy in ALS, Parkinson’s      disease, Alzheimer's disease and Spinal Muscular Atrophy, and a natural      product derived Nerve Pain Treatment (NQ1123), which is being      developed as a prescription drug for a topical nerve pain condition. Galantos Pharma GmbH ( www.galantos.com )      is a German biotechnology company founded in 2005 by Professors Alfred      Maelicke (Mainz) and Ulrich Jordis (Vienna). Both have been intimately      involved in the original development of galantamine, and in bringing the      drug to market. Realizing the limited brain penetration of the      plant-derived drug galantamine, they set out to develop a      pro-galantamine with much higher bioavailability in the brain and      without compliance-compromising gastro-intestinal side effects. In      addition, their new drug candidate Memogain® has the potential of both      neuroprotection and disease-modification. Prof. Maelicke will continue      with Neurodyn as Managing Director Europe. Contacts

Neurodyn Inc. Acquires Memogain® For Dementia in Alzheimer’s Disease

Other Investors

Neurodyn focuses on neuroprotection and the early treatment of neurological diseases within the biotechnology sector. The company offers a portfolio approach to identify, validate, and develop bioactives that serve therapeutic purposes. Neurodyn also provides contract research services to support drug development processes. It was founded in 2003 and is based in Vancouver, British Columbia.

Date
Round	Other Investors
Amount
Investors	Emergence
Valuation	$XXM
Revenue	0 FY undefined
Sources

First funding
Last Funding
Investor	Emergence
Rounds	1 Other Investors
Board Seats
Type	Incubator/Accelerator
Location	Canada

How VCs Use CB Insights

Professional Services

Platform Overview

Neurodyn

Investors Count

Funding, Valuation & Revenue

Neurodyn Investors